• Castro DV, Dizman N, Barragan-Carrillo R, Li X, Agarwal R, Lee A, Mercier BD, Zugman M, Wong MH, Ozay ZI, Goud J, Dukkipati A, Paul T, Chan E, Paul T, Faridi A, Kooner S, Patel J, Ebrahimi H, Jaime-Casas J, Salgia NJ, Hsu J, Chawla NS, Chehrazi-Raffle A, Florez N, Pal SK. Examining adherence to ASCO’s Language of Respect in urothelial carcinoma research. JCO Oncology Advances. In Press.
  
• Jaime-Casas S, Zugman M, Brragan-Carrillo R, Ebrahimi H, Shah K, Yip W, Chan KG, Lau CS, Yu BE, Mercier B, Salgia NJ, Castro DV, Li X, Hsu J, Nguyen C, Chehrazi-Raffle A, Pal SK, Tripathi A. Clinical and pathological predictors for occult lymph node involvement in patients with clinical node-negative bladder cancer undergoing radical cystectomy. Clinical Genitourinary Cancer. 2025 Jul (Epub ahead of print). doi: 10.1016/j.clgc.2025.102405.
  
• Salgia NJ, Khan A, Aubrecht WM, Twoey GC, Chow J, Attwood K, Yu H, Chiello JL, Hansen N, Wasik BJ, Mercier BD, Ebrahimi H, Meza L, Maguire O, Mastri M, Whalen C, Minderman H, Pirrotte P, Byron S, Repasky EA, Singh PK, Bshara W, Wang J, McGray AJR, Abrams SI, Eng KH, Long MD, Pal SK, Kauffman EC, Muhitch JB. Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer Cell. 2025 Aug (Epub ahead of print). doi: 10.1016/j.ccell.2025.07.010.
  
• Salgia NJ, Fujiwara Y, Xu B, George S, Muhitch JB, Kauffman EC. Biological and clinical insight into the prevention and management of metastatic renal cell carcinoma with sarcomatoid component. Eur Urol Focus. 2025 Jun. doi: 10.1016/j.euf.2025.05.011.
  
• Jaime-Casas, Chawla NS, Salgia NJ, Mercier B, Govindarajan A, Li X, Castro DV, Ebrahimi H, Barragan-Carillo R, Zang, PD, LeVee A, Zugman M, Dizman N, Hsu J, Meza L, Zengin Z, Chehrazi-Raffle A, Dorff T, Pal SK, Tripathi A. Comparative genomic characterization of small cell carcinoma of the bladder compared to urothelial carcinoma and small cell lung carcinoma. JCO Precis Oncol. 2025 Apr. doi:10.1200/PO-24-00947
  
• Castro DV, Gebrael G, Meza L, Li X, Tripathi N, Tandar C, Sayegh N, Zengin ZB, Chehrazi-Raffle A, Govindarajan A, Dizman N, Barragan-Carrillo R, Ebrahimi H, Mercier BD, Chawla NS, Jaime-Casas S, Salgia N, Zugman M, Angeles A, Hsu J, Philip EJ, Bergerot CD, Agarwal N, Pal SK. The impact of insurance status on survival outcomes in patients with metastatic renal cell carcinoma. JCO Oncology Advances. 2025 March. doi:10.1200/OA.24.00015
  
• Salgia NJ, Dizman N, Pal SK. Of HIFs and hERVs: Neoantigen generation in kidney cancer. Cancer Cell. 2025 Mar. doi:10.1016/j.ccell.2025.03.001
  
• Barragan-Carrillo R, Salgia N, Eilber KS, Pal SK, Dallas K, Bourlon MT. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with renal cell carcinoma in California. Urol Oncol. 2024 Dec. doi:10.1016/j.urolonc.2024.11.026
  
• Salgia NJ, Zengin Z, Pal SK, Dizman N. Renal cell carcinoma of variant histology: new biological understanding leads to therapeutic advances. Am Soc Clin Oncol Educ Book. 2024 June. doi:10.1200/EDBK_438642.
  
• Ebrahimi H, Battle D, Salgia NJ, Zengin ZB, Dizman N, Meza L, Bergerot CD, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu ST, Chehrazi-Raffle A, Vaishampayan U, Staehler MD, Pal SK. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma receiving systemic therapy. Nutrients. 2024 May. doi:10.3390/nu16111630
  
• Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia NJ, Zengin ZB, Meza L, Chawla N, Castro DV, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer RA, Boehmer L, Pal SK, Chehrazi-Raffle A. Barriers to clinical trial implementation among community care centers. JAMA Network Open. 2024 Apr. doi:10.1001/jamanetworkopen.2024.8739
  
• Salgia NJ, Aubrecht WM, Wang L, Ram B, Wasik BJ, Khan A, Attwood K, Daza J, Long MD, Eng KH, Xu B, Muhitch JB, Kauffman EC. Stratification of renal cell carcinoma patients by abundance of sarcomatoid features reveals differences in survival and underlying pathobiology. European Urology Oncology. 2024 Mar. doi:10.1016/j.euo.2024.02.007
  
• Govindarajan A*, Salgia NJ*, Li H, Castro DV, Mirzapoiazova T, Armstrong B, Zhao D, Mercier BD, Dizman N, Chawla N, Zengin Z, Mela L, Tripathi N, Sayeh N, Chehrazi-Raffle A, Tripathi A, Pal SK. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Frontiers in Immunology. 2023 Aug;14:1182581. doi:10.3389/fimmu.2023.1182581. *Equal contribution
  
• Bergerot CD, Philip EJ, Malhotra J, Bergerot PG, Castro DV, Govindarajan A, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer. Journal of Genetic Counseling. 2023 Sep;00:1-5. doi:10.1002/jgc4.1786
• Bergerot CD, Philip EJ, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clin Genitourin Cancer. 2023 Jun 2:S1558-7673(23)00136-2. doi: 10.1016/j.clgc.2023.05.018. Epub ahead of print.
• Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Roc A, Liu S, Salgia R, Trent J, Altin J, Pal SK. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist. 2023 Mar. Epub ahead of print. doi: 10.1093/oncolo/oyad067.
  
• Zengin Z*, Govindarajan A*, Salgia N*, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercer BD, Ladbuy C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal SK, Dandapani S. Genomic and transcriptomic predictors of response from stereotactic body radiation therpay in patients with metastatic renal cell carcinoma. European Urology Oncology. 2023 Jan; [*Co-first authors]
  
• Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. PMID: 35228755; PMCID: PMC9018425. 
• Malhotra J, Meza L, Salgia N, Pal SK. Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages. In: Necchi A, Spiess PE (eds) Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers (1), 221-227. New York, New York: Springer. 2022 Jan. doi:10.1007/978-3-030-80546-3_17
• Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal SK. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal of Immunotherapy for Cancer. 2021 Mar;9(3):e002009. doi:10.1136/jitch-2020-002009. 
  
• Zengin ZB, Weipert CM, Salgia N, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski LA, Maughan BL, Rathi N, Goel D, Chouieri TK, Agarwal N, Pal SK. Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma. Clinical Cancer Research. 2021 Jun;Epub ahead of print. doi:10.1158/1078-0432.CCR-21-0572. 
• Salgia NJ, Govindarajan A, Pal SK. Second-line nivolumab for patients with metastatic renal cell carcinoma in India: A call for expanding global access to clinical trials. Cancer Research Statistics and Treatment. 2021 Jun;4(2):401-402. doi:10.4103/crst.crst_78_21. 
• Salgia S, Salgia N, Prajapati S, Seghal I, Bautista F, Ruel N, Salgia M, Salgia DA, Salgia R, Pal SK. Twitter as a tool to spread communication regarding genitourinary cancers during the COVID-19 pandemic. Kidney Cancer. 2021 Jun;5(2):73-78. doi:10.3233/KCA-210115.
• Meza L, Salgia NJ, Patel KC, Pal SK. Learning from BISCAY: the future of biomarker-based trial design in bladder cancer. Cancer Cell. 2021 July12;39(7):910:912. doi:10.1016/j.ccell.2021.06.011. 
• Salgia NJ*, Chehrazi-Raffle A*, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine. 2021 Aug;10(16):5671-5680. doi: 10.1002/cam4.4119.
• Stack ME, Salgia N, Vigneswaran WT. (2015) Successful primary repair of a colopericardial fistula: a Late complication of esophageal replacement. Annals of Thoracic Surgery, 100(4):1459-1461. doi:10.1016/j.athoracsur.2014.12.046. 
• Salgia NJ, Pal SK. (2019). Editorial Comment. Journal of Urology, 201(3):548. doi:10.1097/01.JU.0000553713.64297.bb. 
• Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK. (2019). The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions. Current Treatment Options in Oncology, 20(5):41. doi:10.1007/s11864-019-0638-1. 
• Dara YE, Salgia NJ, Pal SK. (2020). Renal Cell Carcinoma. Oncology in the Precision Medicine Era (1):123-134. New York, New York: Springer. doi:10.1007/978-3-030-31471-2 
• Salgia NJ, Feng M, Prajapati D, Harwood R, Dara Y, Ruel N, Salgia M, Pal SK. (2020). Examining the association of academic rank and productivity with metrics of Twitter utilization amongst kidney cancer specialists. Kidney Cancer, 4(2):103-109. Doi:10.3233/KCA-200083. 
• Meng WS, Salgia NJ, Pham NB, Velanker KY, Pal SK. (2020). A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma. Urologic Oncology, S1078-1439(20)30105-8. Published Online Ahead of Print. doi:10.116/j.urolonc.2020.03.108. 
• Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. (2020). Advancing the science and management of renal cell carcinoma: bridging the divide between academic and community practices. Journal of Clinical Medicine, 9(5):1508. doi:10.3390/jem9051508. 
• Salgia NJ, Zengin ZB, Pal SK. (2020). Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances in Medical Oncology. doi:10.1177/1758835920923818. 
• Dizman N, Lyou Y, Salgia NJ, Bergerot PG, Hsu J, Trent J, Byron S, Pal SK. (2020). Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic sequencing analysis. Journal of Immunotherapy for Cancer, 8(2):e000953. doi:10.1136/jitc-2020-000953. 
• Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. (2020). Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. European Urology. S0302-2838(20)30543-1. Published Online Ahead of Print. doi:10.1016/j.eururo.2020.07.011. 
• Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 2021 Feb 1;127(3):354-358. doi: 10.1002/cncr.33238.
  
• Dizman N*, Salgia NJ*, Bergerot PG, Hsu J, Pal SK. Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies. Kidney Cancer. 2020;4(3):159-166. doi:10.3233/KCA-200092.
• Zengin ZB, Salgia NJ, Cherazi-Raffle A, Meza L, Malhotra J, Pal SK. (2020). Immune related adverse events: classification and management appraoches in advanced kidney cancer. The Cancer Journal. In Press. 
• Hansen B, Zhao J, Helfrich K, Li N, Iancau V, Zolotarev A, Zakharkin S, Kalyanasundaram A, Subr M, Dastagir N, Sharma R, Artiga E, Salgia N, Houmsse M, Kahaly O, Janssen P, Mohler P, Mokadam N, Whitson B, Afzal M, Simonetti O, Hummel J, Fedorov V. Unmasking arrhythmogenic hubs of reentry driving persistent atrial fibrillation for patient-specific treatment. Journal of the American Heart Association. 2020;9(19):e017789. doi:10.1161/JAHA.120.017789.
  

SELECTED INVITED TALKS & ORAL PRESENTATIONS

• Salgia NJ. (2019, September 30). Overview of renal cell carcinoma: presentation, treatment, and outcomes. Invited talk at the 2019 TGen – City of Hope Microbiome Retreat in Flagstaff, AZ. 
• Salgia NJ. (2021, October 8). Multiplex analysis of the tumor microenvironment in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response. Rapid abstract presentation at the 2021 Kidney Cancer Research Summit in Philadelphia, PA. 
• Salgia NJ (2023, Feb 22). Modeling the initiation and immunogenicity of sarcomatoid dedifferentiation in renal cell carcinoma. Oral abstract presentation at the 2023 Translational Cancer Centers Consortium Annual Meeting in Seven Springs, PA. 
• Salgia NJ (2023, June 16). Exploring the mediators of the initiation and immunogenicity of sarcomatoid dedifferentiation in renal cell carcinoma. Oral abstract presentation at the 2023 Roswell Park Comprehensive Cancer Center Immunology Retreat in Buffalo, NY. 
• Salgia NJ (2023, Oct 18). Sarcomatoid dedifferentiation promotes immunogenic properties in renal cell carcinoma. Oral abstract presentation at the 2023 25th Annual Upstate New York Immunology Conference in Cooperstown, NY. 
• Salgia NJ. (2023, December 22). Go Big or Go Home: Applying Big Data Analysis to Develop Biological Models and Drive Clinical Advancements in Renal Cell Carcinoma. Invited seminar at the City of Hope Comprehensive Cancer Center Department of Medical Oncology in Duarte, CA. 
• Salgia NJ. (2024, January 3). Impacts of Sarcomatoid Transformation on Immunogenic Activity in Renal Cell Carcinoma. Invited seminar at the Roswell Park Comprehensive Cancer Center Genitourinary Cancers Translational Research Group in Buffalo, NY. 
• Salgia NJ (2024, Feb 22). Unraveling the Paradoxical Immune Biology of Sarcomatoid Renal Cell Carcinoma One Cell at a Time. Oral abstract presentation at the 2024 Translational Cancer Centers Consortium Annual Meeting in Seven Springs, PA. 
• Salgia NJ (2024, May 5). Classification by Sarcomatoid Feature Abundance in Renal Cell Carcinoma Reveals Differential Patient Outcomes and Transcriptomic Features. Moderated Poster Discussion at the 2024 American Urological Association Annual Meeting in San Antonio, TX. 
• Salgia NJ (2024, July 12). Enrichment of Tertiary Lymphoid Structures Provides Novel Insight into Mediators of Anti-Tumor Immune Activity in Sarcomatoid Renal Cell Carcinoma Rapid Abstract presentation at the 2024 Kidney Cancer Research Summit in Boston, MA. 
• Salgia NJ (2024, Sep 20). Applying single cell RNA sequencing of sarcomatoid renal cell carcinoma for the development of a novel transcriptomic biomarker to predict immunotherapy response. Moderated Poster Discussion at the 2024 American Urological Association Northeastern Section Annual Meeting Montreal, QC, CA. 
• Salgia NJ (2024, Oct 15). Interrogating Tertiary Lymphoid Structures to Untangle the Paradoxical Immune Responsiveness of Sarcomatoid Renal Cell Carcinoma. Oral abstract presentation at the 2024 Upstate New York Immunology Conference in Cooperstown, NY. 
• Salgia NJ (2024, Nov 15). Sarc Attack! Employing High-Dimensional Approaches to Turn Sarcomatoid Renal Cell Carcinoma from Predator to Prey. Invited talk at the 2024 Roswell Park Scientific Retreat in Niagara Falls, NY. 
• Salgia NJ (2025, Feb 20). Untangling the paradoxical immune sensitivity of sarcomatoid renal cell carcinoma. Oral abstract presentation at the 2025 Translational Cancer Centers Consortium Annual Meeting in Seven Springs, PA. 
• Salgia NJ (2025, Mar 18). Untangling & applying the paradoxical immune sensitivity of sarcomatoid renal cell carcinoma. Invited talk at the 2025 Keystone Symposium, Cancer Immunotherapy: Clinical Lessons to New Modalities Meeting in Banff, AB, CA. 

FIRST-AUTHORED ABSTRACTS & POSTER PRESENTATIONS

• Salgia NJ, Pal SK, Chung V, Tagawa ST, Picus J, Babiker HM, Wadlow RC, Poore J, Peterson C, & Benaim E. (2019, February 15). Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIa Study. Poster presented at the 2019 ASCO GU Symposium in San Francisco, CA. 
• Salgia NJ, Hansen BJ, Hoummse M, Iancau A, Mosheim A, Li N, Kahali O, Afzal M, Hummel JD, Fedorov VV. (2019, February 20). Impact of Adenosine on Reentrant Driver Characteristics Revealed by Multi-Electrode Mapping in Atrial Fibrillation Patients. Poster presented at the Denman Undergraduate Research Forum at Ohio State University in Columbus, OH. 
• Salgia N, Dizman N, Bergerot PG, Bergerot CD, Hsu J, Pal SK. (2019, October 29). Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients receiving first-line (1L) targeted therapies (TT) for the treatment of metastatic renal cell carcinoma (mRCC). Poster presented at the 2019 City of Hope Poster Day in Duarte, CA. 
• Salgia N, Pal SK, Aix SP, Loriot Y, Dreicer R, Vaishampayan U, Choueiri TK, Schoffski P, Curran D, Liu Y, Lim FL, Neal J, Agarwal N. (2019, November 7). Expansion cohorts of non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC) in COSMIC-021, a phase 1b study of cabozantinib plus atezolizumab. Poster presented at Society for Immunotherapy of Cancer (SITC) 2019 in National Harbor, MD. 
• Salgia NJ, Feng M, Prajapati D, Harwood R, Nissanoff M, Dara Y, Ruel N, Salgia M, Pal SK. (2019, November 15). Association of academic rank and productivity with metrics of Twitter utilization amongst kidney cancer experts. Poster presented at the 18th Annual International Kidney Cancer Symposium in Miami, FL. 
• Salgia N, Dizman N, Bergerot PG, Bergerot CD, Hsu J, Pal SK. (2020, February 15). Progression-Free Survival (PFS) and Overall Survival (OS) Across Ethnicities for Patients with Metastatic Renal Cell Carcinoma (mRCC) Receiving Targeted Therapies (TT) as First-Line (1L) Treatment. Poster presented at the 2020 ASCO GU Symposium in San Francisco, CA. 
• Salgia NJ, Dizman N, Lyou Y, Bergerot PG, Hsu J, Byron SA, Trent JM, Pal SK. (2020, May 29). Genomic and transcriptomic correlates of clinical benefit from immunotherapy and targeted therapy among patients with metastatic renal cell carcinoma (mRCC). Poster presented at the 2020 ASCO Annual Meeting (virtual). 
• Salgia N, Dizman N, Mambetsariev I, Mirzapoiazova T, Zhao D, Kulkarni P, Salgia R, Pal SK. (2020, June 22). Genomic and immunohistochemical characterization of patients with advanced papillary renal cell carcinoma: Focus on exceptional responders. Poster presented at the 2020 AACR Annual Meeting (virtual). 
• Salgia NJ, Zengin Z, Dizman N, Hsu J, Meza L, Chawla NS, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Pal SK, Dandapani S. (2021, April 23). Stereotactic body radiation therapy (SBRT) for prolongation of systemic therapy in oligoprogressive metastatic renal cell carcinoma (mRCC). Poster presented by N Salgia at the 2021 European International Kidney Cancer Symposium (virtual). 
• Salgia NJ, Aubrecht W, Wang L, Ram B, Long M, Eng K, Xu B, Kauffman E, Muhitch J (2023, Jul 14). Stratifying patients based on abundance of sarcomatoid features reveals differential transcriptomes and survival outcomes in sarcomatoid renal cell carcinoma. Poster presented at the 2023 Kidney Cancer Research Symposium. 
• Salgia NJ, Aubrecht WM, Attwood K, Chow J, Eng KH, Wang J, Xu B, Long M, Muhitch J, Kauffman E. (2024, Jul 11). Applying single cell RNA sequencing of sarcomatoid renal cell carcinoma for the development of a novel transcriptomic biomarker to predict immunotherapy response. Poster presented at the 2024 Kidney Cancer Research Symposium. 
• Salgia NJ, Kauffman EK, Muhitch JB. (2025, July 17). Interplay of Tumor-Intrinsic and Microenvironmental Gene Expression Predicts Immune Checkpoint Blockade Response in Metastatic Renal Cell Carcinoma. Poster presented at the 2025 Kidney Cancer Research Symposium.